ABSTRACT
Key biomolecular processes, which regulate primordial ovarian follicle dormancy and early folliculogenesis in mammalian ovaries, are not fully understood. The domestic cat is a useful model to study ovarian folliculogenesis and is the most relevant for developing in vitro growth methods to be implemented in wild felid conservation breeding programs. Previously, RNA-sequencing of primordial (PrF), primary (PF), and secondary follicle (SF) samples from domestic cat implicated ovarian steroidogenesis and steroid reception during follicle development. Here, we aimed to identify which sex steroid biosynthesis and metabolism enzymes, gonadotropin receptors, and sex steroid receptors are present and may be potential regulators. Differential gene expression, functional annotation, and enrichment analyses were employed and protein localization was studied too. Gene transcripts for PGR, PGRMC1, AR (steroid receptors), CYP11A1, CYP17A1, HSD17B1 and HSD17B17 (steroidogenic enzymes), and STS (steroid metabolizing enzyme) were significantly differentially expressed (Q values of ≤0.05). Differential gene expression increased in all transcripts during follicle transitions apart from AR which decreased by the secondary stage. Immunohistochemistry localized FSHR and LHCGR to oocytes at each stage. PGRMC1 immunostaining was strongest in granulosa cells, whereas AR was strongest in oocytes throughout each stage. Protein signals for steroidogenic enzymes were only detectable in SFs. Products of these significantly differentially expressed genes may regulate domestic cat preantral folliculogenesis. In vitro growth could be optimized as all early follicles express gonadotropin and steroid receptors meaning hormone interaction and response may be possible. Protein expression analyses of early SFs supported its potential for producing sex steroids.
Subject(s)
Cats/physiology , Gonadal Steroid Hormones/metabolism , Gonadotropins/metabolism , Ovarian Follicle/physiology , Signal Transduction/physiology , 17-Hydroxysteroid Dehydrogenases/analysis , 17-Hydroxysteroid Dehydrogenases/genetics , Animals , Cytochrome P-450 Enzyme System/analysis , Cytochrome P-450 Enzyme System/genetics , Estradiol Dehydrogenases , Female , Gene Expression Regulation , Gonadal Steroid Hormones/biosynthesis , Ovarian Follicle/enzymology , Receptors, Gonadotropin/analysis , Receptors, Gonadotropin/genetics , Receptors, Gonadotropin/physiology , Receptors, Steroid/analysis , Receptors, Steroid/genetics , Receptors, Steroid/physiology , Sequence Analysis, RNAABSTRACT
This review article centers upon family of gonadotropin hormones which consists of two pituitary hormones - follicle-stimulating hormone (FSH) and luteinizing hormone (LH) as well as one non-pituitary hormone - human chorionic gonadotropin (hCG) secreted by placenta, and their receptors. Gonadotropins play an essential role in proper sexual development, puberty, gametogenesis, maintenance of pregnancy and male sexual differentiation during the fetal development. They belong to the family of glycoprotein hormones thus they constitute heterodimeric proteins built of common α subunit and hormone-specific ß-subunit. Hitherto, several mutations in genes encoding both gonadotropins and their receptors have been identified in humans. Their occurrence resulted in a number of different phenotypes including delayed puberty, primary amenorrhea, hermaphroditism, infertility and hypogonadism. In order to understand the effects of mutations on the phenotype observed in affected patients, detailed molecular studies are required to map the relationship between the structure and function of gonadotropins and their receptors. Nonetheless, in vitro assays are often insufficient to understand physiology. Therefore, several animal models have been developed to unravel the physiological roles of gonadotropins and their receptors.
Subject(s)
Chorionic Gonadotropin/physiology , Follicle Stimulating Hormone/physiology , Luteinizing Hormone/physiology , Animals , Chorionic Gonadotropin/genetics , Female , Female Urogenital Diseases/genetics , Female Urogenital Diseases/physiopathology , Follicle Stimulating Hormone/genetics , Humans , Luteinizing Hormone/genetics , Male , Male Urogenital Diseases/genetics , Male Urogenital Diseases/physiopathology , Models, Animal , Mutation , Phenotype , Pregnancy , Receptors, Gonadotropin/genetics , Receptors, Gonadotropin/physiologyABSTRACT
Gonadal development is precisely regulated by the two gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Much progress on understanding the functions of LH and FSH signaling on gonad development has been achieved in the past decades, mostly from studies in mammals, especially genetic studies in both mouse and human. The functions of both LH and FSH signaling in nonmammalian species are still largely unknown. In recent years, using zebrafish, a teleost phylogenetically distant from mammals, we and others have genetically analyzed the functions of gonadotropins and their receptors through gene knockout studies. In this review, we will summarize the pertinent findings and discuss how the actions of gonadotropin signaling on gonad development have evolved during evolution from fish to mammals.
Subject(s)
Gonadotropins/physiology , Gonads/growth & development , Zebrafish/growth & development , Zebrafish/genetics , Animals , Animals, Genetically Modified , Evolution, Molecular , Female , Gene Knockout Techniques , Gonadotropins/deficiency , Gonadotropins/genetics , Gonads/physiology , Male , Ovary/growth & development , Ovary/physiology , Phylogeny , Ranvier's Nodes , Receptors, Gonadotropin/deficiency , Receptors, Gonadotropin/genetics , Receptors, Gonadotropin/physiology , Signal Transduction , Testis/growth & development , Testis/physiology , Zebrafish/physiology , Zebrafish Proteins/deficiency , Zebrafish Proteins/genetics , Zebrafish Proteins/physiologyABSTRACT
The gonadotropin receptors (luteinising hormone receptor; LHR and follicle-stimulating hormone receptor; FSHR) are G protein-coupled receptors (GPCRs) that play an important role in the endocrine control of reproduction. Thus genetic mutations that cause impaired function of these receptors have been implicated in a number of reproductive disorders. Disease-causing genetic mutations in GPCRs frequently result in intracellular retention and degradation of the nascent protein through misfolding and subsequent recognition by cellular quality control machinery. The discovery and development of novel compounds termed pharmacological chaperones (pharmacoperones) that can stabilise misfolded receptors and restore trafficking and plasma membrane expression are therefore of great interest clinically, and promising in vitro data describing the pharmacoperone rescue of a number of intracellularly retained mutant GPCRs has provided a platform for taking these compounds into in vivo trials. Thienopyrimidine small molecule allosteric gonadotropin receptor agonists (Org 42599 and Org 41841) have been demonstrated to have pharmacoperone activity. These compounds can rescue cell surface expression and in many cases, hormone responsiveness, of a range of retained mutant gonadotropin receptors. Should gonadotropin receptor selectivity of these compounds be improved, they could offer therapeutic benefit to subsets of patients suffering from reproductive disorders attributed to defective gonadotropin receptor trafficking.
Subject(s)
Molecular Chaperones/therapeutic use , Proteostasis Deficiencies/drug therapy , Receptors, Gonadotropin/physiology , Animals , Drug Discovery , Humans , Mutation , Pyrimidines/therapeutic use , Receptors, Gonadotropin/agonistsABSTRACT
Gonadotropins play a central role in the control of male and female reproduction. Selective agonists and antagonists of gonadotropin receptors would be of great interest for the treatment of infertility or as non steroidal contraceptive. However, to date, only native hormones are being used in assisted reproduction technologies as there is no pharmacological agent available to manipulate gonadotropin receptors. Over the last decade, there has been a growing perception of the complexity associated with gonadotropin receptors' cellular signaling. It is now clear that the Gs/cAMP/PKA pathway is not the sole mechanism that must be taken into account in order to understand these hormones' biological actions. In parallel, consistent with the emerging paradigm of biased agonism, several examples of ligand-mediated selective signaling pathway activation by gonadotropin receptors have been reported. Small molecule ligands, modulating antibodies interacting with the hormones and glycosylation variants of the native glycoproteins have all demonstrated their potential to trigger such selective signaling. Altogether, the available data and emerging concepts give rise to intriguing opportunities towards a more efficient control of reproductive function and associated disorders.
Subject(s)
Drug Agonism , Receptors, Gonadotropin/agonists , Receptors, Gonadotropin/metabolism , Animals , Female , Gonadotropins/agonists , Gonadotropins/chemistry , Gonadotropins/pharmacology , Humans , Immunoconjugates/chemistry , Immunoconjugates/pharmacology , Ligands , Male , Models, Biological , Polysaccharides/chemistry , Polysaccharides/pharmacology , Receptors, Gonadotropin/physiology , Signal Transduction/physiology , Substrate SpecificityABSTRACT
Teleosts lack a hypophyseal portal system and hence neurohormones are carried by nerve fibers from the preoptic region to the pituitary. The various cell types in the teleost pituitary are organized in discrete domains. Fish possess two gonadotropins (GtH) similar to FSH and LH in other vertebrates; they are heterodimeric hormones that consist of a common alpha subunit non-covalently associated with a hormone-specific beta subunit. In recent years the availability of molecular cloning techniques allowed the isolation of the genes coding for the GtH subunits in 56 fish species representing at least 14 teleost orders. Advanced molecular engineering provides the technology to produce recombinant GtHs from isolated cDNAs. Various expression systems have been used for the production of recombinant proteins. Recombinant fish GtHs were produced for carp, seabream, channel and African catfish, goldfish, eel, tilapia, zebrafish, Manchurian trout and Orange-spotted grouper. The hypothalamus in fishes exerts its regulation on the release of the GtHs via several neurohormones such as GnRH, dopamine, GABA, PACAP, IGF-I, norepinephrine, NPY, kisspeptin, leptin and ghrelin. In addition, gonadal steroids and peptides exert their effects on the gonadotropins either directly or via the hypothalamus. All these are discussed in detail in this review. In mammals, the biological activities of FSH and LH are directed to different gonadal target cells through the cell-specific expression of the FSH receptor (FSHR) and LH receptor (LHR), respectively, and the interaction between each gonadotropin-receptor couple is highly selective. In contrast, the bioactivity of fish gonadotropins seems to be less specific as a result of promiscuous hormone-receptor interactions, while FSHR expression in Leydig cells explains the strong steroidogenic activity of FSH in certain fish species.
Subject(s)
Fishes/metabolism , Gonadotropins/metabolism , Receptors, Gonadotropin/metabolism , Animals , Female , Fishes/physiology , Gonadotropins/genetics , Gonadotropins/physiology , Hypothalamo-Hypophyseal System/metabolism , Hypothalamo-Hypophyseal System/physiology , Male , Phylogeny , Promoter Regions, Genetic , Receptors, Gonadotropin/genetics , Receptors, Gonadotropin/physiology , SeasonsABSTRACT
The gonadotropins Fsh and Lh interact with their receptors (Fshr and Lhr, respectively) in a highly specific manner in mammals with little overlap in biological activities. In fish, the biological activities seem less clearly separated considering, for example, the steroidogenic potency of both Fsh and Lh. Important determinants of the biological activity are the specificity of hormone-receptor interaction and the cellular site of receptor expression. Here, we report the pharmacological characterization of Atlantic salmon Fshr and Lhr, identify receptor-expressing cells in the ovary, and validate receptor mRNA quantification systems. For the pharmacological studies, we used highly purified coho salmon gonadotropins and found that the Fshr preferentially responded to Fsh, but was also activated by approximately 6-fold higher levels of Lh. The Lhr was specific for Lh and did not respond to Fsh. Photoperiod manipulation was used to generate ovarian tissue samples with largely differing stages of maturation. Specific real-time, quantitative (rtq) PCR assays revealed up to 40-fold (fshr) and up to 350-fold (lhr) changes in ovarian expression levels, which correlated well with the differences in ovarian weight, histology, and circulating oestrogen levels recorded in January and June, respectively. Vitellogenic ovaries were used to localise receptor-expressing cells by in situ hybridization. Granulosa cells of small and large vitellogenic follicles were positive for both receptors. Also theca cells of small and large vitellogenic follicles expressed fshr mRNA, while only in large vitellogenic follicles theca cells were (weakly) positive for lhr mRNA. While only ovulatory Lh levels seem high enough to cross-activate the Fshr, expression by both receptors by granulosa and theca cells suggests that homologous ligand receptor interaction will prevail.
Subject(s)
Receptors, Gonadotropin/metabolism , Salmo salar/metabolism , Animals , Body Weight/drug effects , Cell Line , Chromatography, High Pressure Liquid , Cloning, Molecular , Colforsin/pharmacology , Enzyme-Linked Immunosorbent Assay , Estrogens/blood , Female , Follicle Stimulating Hormone/pharmacology , Gene Expression Regulation/drug effects , Humans , In Situ Hybridization , Luteinizing Hormone/pharmacology , Ovary/drug effects , Ovary/metabolism , Receptors, FSH/genetics , Receptors, FSH/metabolism , Receptors, FSH/physiology , Receptors, Gonadotropin/genetics , Receptors, Gonadotropin/physiology , Receptors, LH/genetics , Receptors, LH/metabolism , Receptors, LH/physiology , Salmo salar/geneticsABSTRACT
The TSH receptor (TSHR) together with the homologous lutropin/choriogonadotropin receptor and the follitropin receptor are glycoprotein hormone receptors (GPHRs). They constitute a subfamily of the rhodopsin-like G protein-coupled receptors with seven transmembrane helices. GPHRs and their corresponding hormones are pivotal proteins with respect to a variety of physiological functions. The identification and characterization of intra- and intermolecular signaling determinants as well as signaling mechanisms are prerequisites to gaining molecular insights into functions and (pathogenic) dysfunctions of GPHRs. Knowledge about activation mechanisms is fragmentary, and the specific aspects have still not been understood in their entirety. Therefore, here we critically review the data available for these receptors and bring together structural and functional findings with a focus on the important large extracellular portion of the TSHR. One main focus is the particular function of structural determinants in the initial steps of the activation such as: 1) hormone binding at the extracellular site; 2) hormone interaction at a second binding site in the hinge region; 3) signal regulation via sequence motifs in the hinge region; and 4) synergistic signal amplification by cooperative effects of the extracellular loops toward the transmembrane region. Comparison and consolidation of data from the homologous glycoprotein hormone receptors TSHR, follitropin receptor, and lutropin/choriogonadotropin receptor provide an overview of extracellular mechanisms of signal initiation, conduction, and regulation at the TSHR and homologous receptors. Finally, we address the issue of structural implications and suggest a refined scenario for the initial signaling process on GPHRs.
Subject(s)
Extracellular Space/metabolism , Receptors, Gonadotropin/physiology , Receptors, Thyrotropin/chemistry , Receptors, Thyrotropin/physiology , Thyrotropin/physiology , Amino Acid Sequence , Animals , Extracellular Space/physiology , Humans , Models, Biological , Models, Molecular , Molecular Sequence Data , Receptors, Gonadotropin/chemistry , Receptors, Gonadotropin/metabolism , Receptors, Thyrotropin/metabolism , Sequence Homology, Amino Acid , Signal Transduction , Structure-Activity Relationship , Thyrotropin/chemistry , Thyrotropin/metabolismABSTRACT
This report aimed to establish, using African catfish, Clarias gariepinus, as model species, a basis for understanding a well-known, although not yet clarified, feature of male fish reproductive physiology: the strong steroidogenic activity of FSHs. Assays with gonadotropin receptor-expressing cell lines showed that FSH activated its cognate receptor (FSHR) with an at least 1000-fold lower EC50 than when challenging the LH receptor (LHR), whereas LH stimulated both receptors with similar EC50s. In androgen release bioassays, FSH elicited a significant response at lower concentrations than those required to cross-activate of the LHR, indicating that FSH stimulated steroid release via FSHR-dependent mechanisms. LHR/FSHR-mediated stimulation of androgen release was completely abolished by H-89, a specific protein kinase A inhibitor, pointing to the cAMP/protein kinase A pathway as the main route for both LH- and FSH-stimulated steroid release. Localization studies showed that intratubular Sertoli cells express FSHR mRNA, whereas, as reported for the first time in a vertebrate, catfish Leydig cells express both LHR and FSHR mRNA. Testicular FSHR and LHR mRNA expression increased gradually during pubertal development. FSHR, but not LHR, transcript levels continued to rise between completion of the first wave of spermatogenesis at about 7 months and full maturity at about 12 months of age, which was associated with a previously recorded approximately 3-fold increase in the steroid production capacity per unit testis weight. Taken together, our data strongly suggest that the steroidogenic potency of FSH can be explained by its direct trophic action on FSHR-expressing Leydig cells.
Subject(s)
Leydig Cells/physiology , Receptors, FSH/physiology , Testis/physiology , Androgens/metabolism , Animals , Catfishes/growth & development , Cyclic AMP-Dependent Protein Kinases/metabolism , Gonadotropins/genetics , Gonadotropins/pharmacology , Male , Receptors, Gonadotropin/drug effects , Receptors, Gonadotropin/physiology , Recombinant Proteins/pharmacology , Sexual Maturation , Testis/growth & developmentABSTRACT
Introdução: A puberdade precoce central ocorre principalmente devido a ativação precoce do eixo hipotalâmico-hipofisário-gonadal e conseqüentemente ao aumento do hormônios gonadotróficos. A prematura ativação desse eixo não envolve apenas mudanças físicas precoces da puberdade, mas também aceleração do crescimento linear e aceleração da maturação óssea, que leva a fusão das epífises ósseas de maneira prematura e à diminuição da altura final. Objetivo: Identificar a altura final de pacientes que apresentaram Puberdade Precoce Central atendidos no Serviço de Endocrinologia Pediátrica do Hospital Infantil Joana de Gusmão. Métodos: Foram avaliados os registros de pacientes que haviam atingido a AF no período de 1997-2007. As variáveis analisadas foram: sexo, idade cronológica, idade óssea, idade ao diagnóstico, idade ao atingir a altura final, tempo de tratamento até altura final, tempo de acompanhamento até a altura final, tratamento utilizado, altura no início e término do tratamento, altura predita pelo método de Bayley Pinneau, altura-alvo e altura final ( transformada em escore z). Resultados: Foram incluídos 56 pacientes, 96,4 % do sexo feminino e 90,75 % dos pacientes apresentavam PPC idiopática. Os pacientes masculinos foram tratados com análogo do hormônio liberador de gonadotrofinas por 2,7 anos em média, enquanto que as pacientes femininas foram tratadas durante 3,1 anos. A altura final foi alcançada aos 15,1 anos nos meninos e 14,2 anos nas meninas.Conclusões: A média de altura final foi 171,25 cm no sexo masculino e 160,77 cm no sexo feminino. O escore-z de AF foi de -0,55 desvios padrão da média nos meninos e 0,04 desvios padrão da média nas meninas. A diferença entre altura final e altura alvo foi de -5,25 cm nos meninos e 2,4 cm nas meninas.
Background: Central precocious puberty is mainly due to the precocious activation of hypothalamic-pituitary-gonadal axis leading to an increase of gonadotropic hormones. The premature activation of this axis it involves not only early physical changes of puberty, but also linear growth acceleration and acceleration of bone maturation, which leads to early epiphyseal fusion and short adult height. Objective: To identify final height in central precocious puberty patients treated at Pediatric Endocrinology Service of Hospital Infantil Joana de Gusmão. Methods: The study evaluated the registration of patients that had reached the final height between 1997-2007. Data included sex, chronological age, bone age, age at diagnosis, age at final height, duration of treatment, duration of accompaniment from the start of treatment to final height, treatment used, height at the start and at the end of treatment, predicted height by Bayley Pinneau method, target height and final height (these are transformed in z-score). Results: Fifty six patients were involved. 96,4 % were female sex and 90,75 % had idiopathic central precocious puberty. The males were treated with Gonadotropin Releasing Hormone Analogue by 2,7 years and females were treated by 3,1 years. Final height was reached at 15,1 years in boys and 14,2 years in girls. Conclusions: Final height average was 171,25 cm in males and 160,77 cm in females. The z-score of final height was -0,55 standard deviation of average in boys and 0,04 standard deviation of average in girls. The difference between final height and target height were -5,25 cm in boys and 2,4 cm in girls.
Subject(s)
Humans , Male , Female , Child , Adolescent , Body Height , Growth Disorders , Puberty, Precocious , Receptors, Gonadotropin , Body Height/physiology , Body Height/genetics , Puberty, Precocious/complications , Puberty, Precocious/diagnosis , Puberty, Precocious/enzymology , Puberty, Precocious/metabolism , Receptors, Gonadotropin/physiology , Receptors, Gonadotropin/metabolism , Receptors, Gonadotropin/blood , Growth Disorders/classification , Growth Disorders/diagnosis , Growth Disorders/physiopathology , Growth Disorders/metabolismABSTRACT
Although glycoprotein hormones are usually regarded as pituitary-endocrine signals, their receptors can be found in non-endocrine tissues. High expression of selected receptors in the pituitary-endocrine axis is key to mammalian endocrine regulation. We hypothesize that peripheral receptor distribution during development and in secondary organs reflects older but still-applicable functions, with their concentration in the pituitary a more recent evolutionary advancement. We extrapolate additional functions of these receptors by analogy of homologous receptors in older phyla, with emphasis on the bony fishes (teleosts). Studies of the multiple roles of the glycoprotein hormone receptors are likely to uncover novel endocrine functions and axes, and highlight the potential of these receptors as novel therapeutic targets.
Subject(s)
Receptors, Gonadotropin/metabolism , Receptors, Gonadotropin/physiology , Amino Acid Sequence , Animals , Evolution, Molecular , Fishes , Humans , Models, Biological , Models, Molecular , Molecular Sequence Data , Receptors, LHRH/physiology , Receptors, Melanocortin/physiology , Receptors, Thyrotropin/physiology , Sequence Homology, Amino Acid , Tissue DistributionABSTRACT
The follicle-stimulating hormone (FSH) and the luteinizing hormone (LH) play central roles in vertebrate reproduction. They act through their cognate receptors to stimulate testicular and ovarian functions. The present study reports the cloning and characterization of two sea bass (Dicentrarchus labrax) cDNAs encoding a FSH receptor (sbsFSHR) and a LH receptor (sbsLHR). The mature proteins display typical features of the glycoprotein hormone receptor family members, but the sbsFSHR also contains some remarkable differences when compared with other fish or mammalian FSHRs. Among them, a distinct extracellular N-terminal cysteine domain as regards to its length and cysteine number, and the presence of an extra leucine-rich repeat. Expression analysis revealed that the sbsFSHR is exclusively expressed in gonadal tissues, specifically in the follicular wall of previtellogenic and early-vitellogenic follicles. On the contrary, sbsLHR mRNA was found to be widely distributed in sea bass somatic tissues. When stably expressed in mammalian cell lines, sbsFSHR was specifically stimulated by bovine FSH, while sbsLHR was activated by both bovine LH and FSH. Nevertheless, specific stimulation of the sbsLHR was observed when recombinant sea bass gonadotropins were used. The isolation of a FSHR and a LHR in sea bass opens new ways to study gonadotropin action in this species.
Subject(s)
Bass/genetics , Cloning, Molecular , DNA, Complementary/isolation & purification , Gene Expression , Receptors, Gonadotropin/genetics , Receptors, Gonadotropin/physiology , Amino Acid Sequence , Animals , Base Sequence , CHO Cells , Cricetinae , Cricetulus , Female , Gene Expression Regulation/drug effects , Gonadotropins/pharmacology , Male , Molecular Sequence Data , Phylogeny , Receptors, FSH/genetics , Receptors, Gonadotropin/metabolism , Receptors, LH/genetics , Sequence Homology, Amino Acid , Tissue DistributionABSTRACT
Ovarian epithelial cancer (OEC) accounts for 90% of all ovarian cancers and is the leading cause of death from gynecological cancers in North America and Europe. Despite its clinical significance, the factors that regulate the development and progression of ovarian cancer are among the least understood of all major human malignancies. The two gonadotropins, FSH and LH, are key regulators of ovarian cell functions, and the potential role of gonadotropins in the pathogenesis of ovarian cancer is suggested. Ovarian carcinomas have been found to express specific receptors for gonadotropins. The presence of gonadotropins in ovarian tumor fluid suggests the importance of these factors in the transformation and progression of ovarian cancers as well as being prognostic indicators. Functionally, there is evidence showing a direct action of gonadotropins on ovarian tumor cell growth. This review summarizes the key findings and recent advances in our understanding of these peptide hormones in ovarian cancer development and progression and their role in potential future cancer therapy. We will first discuss the supporting evidence and controversies in the "gonadotropin theory" and the use of animal models for exploring the involvement of gonadotropins in the etiology of ovarian cancer. The role of gonadotropins in regulating the proliferation, survival, and metastasis of OEC is next summarized. Relevant data from ovarian surface epithelium, which is widely believed to be the precursor of OEC, are also described. Finally, we will discuss the clinical applications of gonadotropins in ovarian cancer and the recent progress in drug development.
Subject(s)
Gonadotropins/physiology , Neoplasms, Glandular and Epithelial/etiology , Neoplasms, Glandular and Epithelial/physiopathology , Ovarian Neoplasms/etiology , Ovarian Neoplasms/physiopathology , Animals , Disease Models, Animal , Female , Humans , Mice , Neoplasms, Glandular and Epithelial/pathology , Ovarian Neoplasms/pathology , Rats , Receptors, Gonadotropin/physiologyABSTRACT
Las kisspeptinas fueron inicialmente identificadas como un grupo de péptidos estructuralmente relacionados, codificados por el gen KiSS-1, con capacidad de inhibir la metástasis de ciertos tumores mediante la activación del receptor acoplado a proteínas G, GPR54. No obstante, a finales de 2003, sendas publicaciones demostraron que mutaciones inactivantes del gen GPR54 se asocian a ausencia de pubertad e hipogonadismo hipogonadotropico, tanto en humanos como en roedores, lo que puso de manifiesto el papel clave del sistema ligando-receptor KiSS-1/GPR54 en el control del eje reproductor en general, y de los mecanismos de activación de la pubertad en particular. Estas observaciones iniciales se han visto sustanciadas en los últimos 3 años a través de numerosos estudios experimentales en diversas especies (desde roedores hasta humanos), que han permitido establecer el papel absolutamente crucial de las kisspeptinas y su receptor en la regulación de diversas facetas de la función reproductora. En este trabajo revisaremos los aspectos más sobresalientes del papel del sistema KiSS-1/GPR54 en el control del eje gonadotrópico, con especial atención a la descripción de la implicación de las kisspeptinas en la activación puberal del sistema reproductor y su modulación por factores relevantes, tales como el estado energético y metabólico del organismo (AU)
Kisspeptins were first identified as a family of structurally-related peptides, encoded by the KiSS-1 gene, with ability to inhibit tumor metastasis through binding to the G protein-coupled receptor GPR54. However, in late 2003, two independent publications demonstrated the presence of inactivating mutations of GPR54 gene in patients suffering lack of puberty onset and hypogonadotropic hypogonadism; a phenotype which was also observed in mice with genetic inactivation of GPR54. These observations disclosed the essential roles of the ligand/receptor system KiSS-1/ GPR54 in the control of reproductive function in general, and in the regulation of puberty onset in particular. These contentions have been fully substantiated during the last three years, by a number of experimental studies in different species (from Mouse and rats to humans), which have defined the indispensable role of kisspeptins and their receptor in the regulation of different aspects of reproduction. In the present article, we will review the most salient facets of the KiSS-1/GPR54 system in the control of the gonadotropic axis, with special emphasis on the potential involvement of kisspeptins in the pubertal activation of the reproductive system and its modulation by key regulatory factors, such as energy balance and the metabolic status of the organism (AU)
Subject(s)
Humans , Kisspeptins/physiology , Hypogonadism/physiopathology , Gonadotropin-Releasing Hormone , Gonadotropins/pharmacokinetics , Receptors, Gonadotropin/physiology , Reproduction/physiology , Puberty/physiologyABSTRACT
Ovarian carcinoma continues to be the leading cause of death due to gynecological malignancy. Epidemiologic studies indicate that steroid hormones play roles in ovarian carcinogenesis. Gonadotropins, estrogen, and androgen may be causative factors, while gonadotropin-releasing hormone and progesterone may be protective factors in ovarian cancer pathogenesis. Experimental studies have shown that hormonal receptors are expressed in ovarian cancer cells and mediate the growth-stimulatory or growth-inhibitory effects of the hormones on these cells. Hormonal therapeutic agents have been evaluated in several clinical trials. Most of these trials were conducted in patients with recurrent or refractory ovarian cancer, with modest efficacy and few side effects. Better understanding of the mechanisms through which hormones affect cell growth may improve the efficacy of hormonal therapy. Molecular markers that can reliably predict major clinical outcomes should be investigated further in well-designed trials.
Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Carcinoma/drug therapy , Ovarian Neoplasms/drug therapy , Androgens/physiology , Carcinoma/etiology , Estrogens/physiology , Female , Gonadotropin-Releasing Hormone/physiology , Gonadotropins/physiology , Humans , Models, Biological , Ovarian Neoplasms/etiology , Progesterone/physiology , Receptors, Gonadotropin/physiology , Receptors, LHRH/physiologySubject(s)
Spermatogenesis , Animals , Autocrine Communication/physiology , Feedback, Physiological/physiology , Follicle Stimulating Hormone/physiology , Gonadotropin-Releasing Hormone/physiology , Humans , Hypothalamus/physiology , Luteinizing Hormone/physiology , Male , Paracrine Communication/physiology , Pituitary Gland, Anterior/physiology , Receptors, Gonadotropin/physiology , Testis/cytology , Testis/physiology , Testosterone/biosynthesis , Vas Deferens/cytologyABSTRACT
During the last 10 years, numerous activating and inactivating mutations have been detected in the genes encoding the two gonadotrophins, luteinising hormone (LH) and follicle-stimulating hormone (FSH), as well as their cognate receptors (R), LHR and FSHR. Because activation of the hypothalamic-pituitary-gonadal axis is a crucial event in the onset and progression of puberty, mutations affecting gonadotrophin action have major influence on this developmental process. Many of the phenotypic effects observed have been expected on the basis of the existing information about gonadotrophin action (e.g. delayed puberty), but also many unexpected findings have been made, including the lack of phenotype in women with activating LHR mutations, and the discrepancy in phenotypes of men with inactivating mutations of FSHbeta (azoospermia and infertility) and FSHR (oligozoospermia and subfertility). Some of the possible mutations, such as inactivating LHbeta and activating FSHR mutations in women, have not yet been detected. Genetically modified mice provide relevant phenocopies for the human mutations and serve as good models for studies on molecular pathogenesis of these conditions. They may also predict phenotypes of the mutations that have not yet been detected in humans. We review here briefly the effects of gonadotrophin subunit and receptor mutations on puberty in humans and contrast the information with findings on genetically modified mice with similar mutations.
Subject(s)
Gonadal Disorders/genetics , Mutation , Pituitary Diseases/genetics , Sexual Maturation/genetics , Animals , Follicle Stimulating Hormone/deficiency , Follicle Stimulating Hormone/genetics , Follicle Stimulating Hormone/physiology , Gonadotropins/deficiency , Gonadotropins/genetics , Gonadotropins/physiology , Humans , Luteinizing Hormone/deficiency , Luteinizing Hormone/genetics , Luteinizing Hormone/physiology , Mice , Mice, Knockout , Mice, Transgenic , Pituitary Gland , Protein Subunits/deficiency , Protein Subunits/genetics , Puberty/genetics , Puberty/physiology , Receptors, FSH/deficiency , Receptors, FSH/genetics , Receptors, FSH/physiology , Receptors, Gonadotropin/deficiency , Receptors, Gonadotropin/genetics , Receptors, Gonadotropin/physiology , Receptors, LH/deficiency , Receptors, LH/genetics , Receptors, LH/physiology , TransfectionABSTRACT
The gonadotropin receptors are G-protein-coupled receptors with unique structural and functional features, consisting of two halves. The N-terminal extracellular half (exodomain) binds the hormones, whereas the C-terminal membrane-associated half (endodomain) is responsible for receptor activation. In this review, the novel ternary interactions, contact points and mutual modulations among the exodomain, endodomain and hormone for hormone binding and signal generation are described based on the latest observations. This discussion is contrary to the yiew that the exodomain and endodomain are independent, at least functionally, and provides new insights into the receptor mechanisms for the gonadotropins and other G-protein-coupled receptors.